Funding
Funding not disclosed
Founders
Product
Problem
Current non-animal models for studying and treating diseases often suffer from being cumbersome, inconsistent, and unreliable, hindering their widespread adoption in biomedical research and clinical applications. These shortcomings stem from limitations in the methods used to create these models.
Solution
Cymphony Bio is developing Dynamic Interface Printing (DIP), a biofabrication solution designed to create precise, reproducible, and consistent models of human disease. Their technology enables researchers and clinicians to replicate human diseases, study their mechanisms, and design new therapies with unprecedented flexibility. By offering a new means of production for replicating human diseases, Cymphony Bio aims to introduce biofabrication into clinical decision-making, providing meaningful results for biomarker detection and predictive medicine. The company strives to make biofabrication accessible to researchers worldwide, accelerating the development of therapies for patients in need.
Target Audience
Cymphony Bio's primary customers are researchers and clinicians in the biomedical field who are developing and utilizing non-animal models for disease research, drug discovery, and personalized medicine.
Features
- Dynamic Interface Printing (DIP) technology for precise control over biofabrication processes.
- High printing speed, exceeding 800 µm/s.
- High resolution, creating features down to 10 µm.
- Rapid fabrication time, as low as 15 seconds.
- Freedom of print volume, offering 100% flexibility.
- Control over 3D cellular arrangement with frequencies ranging from 5 to 500 Hz.
- Material agnostic, supporting a wide range of 405 nm materials.